PHAXIAM Therapeutics (PHXM) 6-K ERYTECH ReportsTop-line Results of Phase 2b Study of Eryaspase for the Treatment of AML

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE13a-16 OR15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the Month of December 2017

Commission File Number:001-38281

ERYTECH Pharma S.A.

(Translation of registrant’s name into English)

Bâtiment Adénine, 60 Avenue Rockefeller

69008 Lyon France

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form20-F or Form40-F:

Form20-F  ☒            Form40-F  ☐

Indicate by check mark if the registrant is submitting the Form6-K in paper as permitted by RegulationS-T Rule 101(b)(1):  ☐

Indicate by check mark if the registrant is submitting the Form6-K in paper as permitted by RegulationS-T Rule 101(b)(7):  ☐

EXHIBIT LIST

Exhibit	Description
99.1	Press Release dated December 8, 2017.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	ERYTECH Pharma S.A.
Date: December 8, 2017	By:	/s/ Eric Soyer
	Name	Eric Soyer
	Title:	Chief Financial Officer and Chief Operating Officer